Systemic Treatment of Sarcoidosis

REFERENCES

• James DG, Carstairs LS, Trowell J, Sharma OP. Treatment of sarcoidosis: report of a controlled therapeutic trial. Lancet. 1967;2:526–528.
   PubMed Web of Science ®Google Scholar
• Selroos O, Sellergren TL. Corticosteroid therapy of pulmonary sarcoidosis: a prospective evaluation of alternate day and daily dosage in stage II disease. Scand J Respir Dis. 1979;60:215–221.
   PubMedGoogle Scholar
• Kropp R, Goebel D, Matthiessen W, et al. Comparison of 3 times weekly versus daily corticosteroid administration in sarcoidosis: a prospective, randomized multicenter study of the Scientific Society for the Therapy of Lung Diseases. Prax Klin Pneumol. 1986;40:123–128.
   Google Scholar
• Rizzato G, Riboldi A, Imbimbo B, Torresin A, Milani S. The long-term efficacy and safety of two different corticosteroids in chronic sarcoidosis. Respir Med. 1997;91:449–460.
   PubMed Web of Science ®Google Scholar
• Zych D, Pawlicka L, Zieliński J. Comparison of the effectiveness of budesonide and prednisone in the maintenance treatment of pulmonary sarcoidosis. Pol Arch Med Wewn. 1992;88:30–37.
   Google Scholar
• Pietinalho A, Tukiainen P, Haahtela T, Persson T, Selroos O. Oral prednisolone followed by inhaled budesonide in newly diagnosed pulmonary sarcoidosis: a double-blind, placebo-controlled multicenter study. Finnish Pulmonary Sarcoidosis Study Group. Chest. 1999;116:424–431.
   PubMed Web of Science ®Google Scholar
• Pietinalho A, Tukiainen P, Haahtela T, Persson T, Selroos O; Finnish Pulmonary Sarcoidosis Study Group. Early treatment of stage II sarcoidosis improves 5-year pulmonary function. Chest. 2002;121:24–31.
   PubMed Web of Science ®Google Scholar
• Zych D, Pawlicka L, Zielinski J. Inhaled budesonide vs prednisone in the maintenance treatment of pulmonary sarcoidosis. Sarcoidosis. 1993;10:56–61.
   PubMedGoogle Scholar
• Milman N, Graudal N, Grode G, Munch E. No effect of high-dose inhaled steroids in pulmonary sarcoidosis: a double-blind, placebo-controlled study. J Intern Med. 1994;236:285–290.
   PubMed Web of Science ®Google Scholar
• Alberts C, van der Mark TW, Jansen HM. Inhaled budesonide in pulmonary sarcoidosis: a double-blind, placebo-controlled study. Dutch Study Group on Pulmonary Sarcoidosis. Eur Respir J. 1995;8:682–688.
   PubMed Web of Science ®Google Scholar
• du Bois RM, Greenhalgh PM, Southcott AM, Johnson NM, Harris TA. Randomized trial of inhaled fluticasone propionate in chronic stable pulmonary sarcoidosis: a pilot study. Eur Respir J. 1999;13:1345–1350.
   PubMed Web of Science ®Google Scholar
• Rossman MD, Newman LS, Baughman RP, et al. A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2006;23:201–208.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Drent M, Kavuru M, et al. Sarcoidosis Investigators. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med. 2006;174:795–802.
   PubMed Web of Science ®Google Scholar
• Judson MA, Baughman RP, Costabel U, et al. Centocor T48 Sarcoidosis Investigators. Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial. Eur Respir J. 2008;31:1189–1196.
   PubMed Web of Science ®Google Scholar
• Stern BJ, Schonfeld SA, Sewell C, Krumholz A, Scott P, Belendiuk G. The treatment of neurosarcoidosis with cyclosporine. Arch Neurol. 1992;49:1065–1072.
   PubMed Web of Science ®Google Scholar
• Wyser CP, van Schalkwyk EM, Alheit B, Bardin PG, Joubert JR. Treatment of progressive pulmonary sarcoidosis with cyclosporin A: a randomized controlled trial. Am J Respir Crit Care Med. 1997;156:1371–1376.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Winget DB, Lower EE. Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial. Sarcoidosis Vasc Diffuse Lung Dis. 2000;17:60–66.
   PubMed Web of Science ®Google Scholar
• Baltzan M, Mehta S, Kirkham TH, Cosio MG. Randomized trial of prolonged chloroquine therapy in advanced pulmonary sarcoidosis. Am J Respir Crit Care Med. 1999;160:192–197.
   PubMed Web of Science ®Google Scholar
• Park MK, Fontana Jr Babaali, H, et al. Steroid-sparing effects of pentoxifylline in pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2009;26:121–131.
   PubMed Web of Science ®Google Scholar
• Reich JM. Adverse long-term effect of corticosteroid therapy in recent-onset sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2003;20:227–34.
   Google Scholar
• Paramothayan NS, Lasserson TJ, Jones PW. Corticosteroids for pulmonary sarcoidosis. Cochrane Database Syst Rev. 2005;:CD001114.
   Google Scholar
• Schutt AC, Bullington WM, Judson MA. Pharmacotherapy for pulmonary sarcoidosis: a Delphi consensus study. Respir Med. 2010;104:717–723.
   PubMed Web of Science ®Google Scholar
• King CS, Kelly W. Treatment of sarcoidosis. Dis Mon. 2009;55:704–718.
   Google Scholar
• Baughman RP, Costabel U, du Bois RM. Treatment of sarcoidosis. Clin Chest Med. 2008;29:533–548, ix–x.
   PubMed Web of Science ®Google Scholar
• Israel HL, Sones M, Harrell D. Cortisone treatment of sarcoidosis: experience with thirty-six cases. J Am Med Assoc. 1954;156:461–466.
   PubMed Web of Science ®Google Scholar
• Gupta SK. Treatment of sarcoidosis patients by steroid aerosol: a ten-year prospective study from eastern India. Sarcoidosis. 1989;6:51–54.
   Google Scholar
• Pietinalho A, Tukiainen P, Haahtela T, Persson T, Selroos O. Early treatment of stage II sarcoidosis improves 5-year pulmonary function. Chest. 2002;121:24–31.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Lower EE. Alternatives to corticosteroids in the treatment of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 1997;14:121–130
   Google Scholar
• Pacheco Y, Marechal C, Marechal F, Biot N, Perrin Fayolle M. Azathioprine treatment of chronic pulmonary sarcoidosis. Sarcoidosis. 1985;2:107–113.
   PubMedGoogle Scholar
• Kataria YP. Chlorambucil in sarcoidosis. Chest. 1980;78:36–43.
   PubMed Web of Science ®Google Scholar
• Gibson GJ. Sarcoidosis: old and new treatments. Thorax. 2001;56:336–339.
   PubMedGoogle Scholar
• Siltzbach LE, Teirstein AS. Chloroquine therapy in 43 patients with intrathoracic and cutaneous sarcoidosis. Acta Med Scand Suppl. 1964;425:302–308.
   PubMedGoogle Scholar
• Sharma OP. Effectiveness of chloroquine and hydroxychloroquine in treating selected patients with sarcoidosis with neurological involvement. Arch Neurol. 1998;55:1248–1254.
   PubMed Web of Science ®Google Scholar
• Field S, Regan AO, Sheahan K, Collins P. Recalcitrant cutaneous sarcoidosis responding to adalimumab but not to etanercept. Clin Exp Dermatol. 2010;35:795–796.
   PubMedGoogle Scholar
• Patel SR. Systemic sarcoidosis with bone marrow involvement responding to therapy with adalimumab: a case report. J Med Case Rep. 2009;3:8573.
   PubMedGoogle Scholar
• Massara A, Cavazzini L, La Corte R, Trotta F. Sarcoidosis appearing during anti-tumor necrosis factor alpha therapy: a new “class effect” paradoxical phenomenon. Two case reports and literature review. Semin Arthritis Rheum. 2010;39:313–319.
   PubMed Web of Science ®Google Scholar
• Gibson GJ, Prescott RJ, Muers MF, et al. British Thoracic Society Sarcoidosis study: effects of long term corticosteroid treatment. Thorax. 1996;51:238–247.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Lower EE, Bradley DA, Raymond LA, Kaufman A. Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial. Chest. 2005;128:1062–1047.
   PubMed Web of Science ®Google Scholar
• Rothova A. Ocular involvement in sarcoidosis. Br J Ophthalmol. 2000;84:110–116.
   PubMed Web of Science ®Google Scholar
• Edelsten C, Pearson A, Joynes E, Stanford MR, Graham EM. The ocular and systemic prognosis of patients presenting with sarcoid uveitis. Eye (Lond). 1999;13:748–753.
   PubMedGoogle Scholar
• Dev S, McCallum RM, Jaffe GJ. Methotrexate treatment for sarcoid-associated panuveitis. Ophthalmology. 1999;106:111–118.
   PubMed Web of Science ®Google Scholar
• Bhat P, Cervantes-Castañeda RA, Doctor PP, Anzaar F, Foster CS. Mycophenolate mofetil therapy for sarcoidosis-associated uveitis. Ocul Immunol Inflamm. 2009;17:185–190.
   PubMed Web of Science ®Google Scholar
• Dios Castro E, Herreras Cantalapiedra JM, Calonge Cano M, Osés S. Ocular sarcoidosis: retrospective study of 18 cases. Arch Soc Esp Oftalmol. 2002;77:301–308.
   Google Scholar
• Petropoulos IK, Vaudaux JD, Guex-Crosier Y. Anti-TNF-alpha therapy in patients with chronic non-infectious uveitis: the experience of Jules Gonin Eye Hospital. Klin Monbl Augenheilkd. 2008;225:457–461.
   PubMed Web of Science ®Google Scholar
• Murray PI. Idiopathic (autoimmune) sight-threatening uveitis. In: Wormald R, Smeeth L, Henshaw K, eds. Evidence-Based Ophthalmology. New York: Informa Healthcare;2004: 167–173.
   Google Scholar
• Doycheva D, Deuter C, Stuebiger N, Zierhut M. Interferon-alpha-associated presumed ocular sarcoidosis. Graefes Arch Clin Exp Ophthalmol. 2009;247:675–680.
   PubMed Web of Science ®Google Scholar